Overview of Assets


Our Priority and Growth Potential Assets give investors access to life sciences businesses with unique exposure across diverse modalities, therapeutic areas and geographies.

Our assets are largely maturing clinical development or commercial companies, nearing significant value inflection or realisation points, in which we hold meaningful stakes.

4 Priority Assets


Our 4 Priority Assets are those which we believe will generate the most significant returns for Malin. We will focus our capital and operational resources on these assets.

Our strategic objective is to support value creation in the Priority Assets.

Malin Equity: 9%

Discover more

Malin Equity: 8%

Discover more

Malin Equity: 24%

Discover more

Malin Equity: 15%

Discover more
71%
Priority Assets
  • Jun-19 IPEV
    fair value
    breakdown

29%
Growth Potential Assets

6 Growth Potential Assets


We will continue to support the progression of these assets as they target important strategic, scientific and operational milestones.

Early-stage assets

Revenue generative assets

Public equity

Malin Equity: 14%

Discover more

Malin Equity: 38%

Discover more

Malin Equity: 10%

Discover more

Malin Equity: 17%

Discover more

Malin Equity: 11%

Discover more

Malin Equity: 65%

Discover more